Darrin Stuart

Dr. Darrin Stuart has spent the last 20 years leading and mentoring teams in small molecule drug discovery in the oncology therapeutic area. Darrin is the Chief Scientific Officer at Scorpion Therapeutics. Prior to joining Scorpion, Darrin was executive director of cancer biology and drug discovery at Novartis where he oversaw the oncology small molecule portfolio at the Cambridge, Massachusetts site. Over the course of 14 years at Novartis, Darrin led and oversaw 10 oncology small molecule programs into first-in-human trials. Notably, Darrin was the project leader for the encorafenib program which is now approved to treat patients with BRAFV600mut melanoma and colorectal cancer. Darrin also led an active basic research lab which published multiple high impact manuscripts on MAPK pathway biology and therapeutics. Darrin joined Novartis through the acquisition of Chiron where he held roles of increasing responsibility, including project and group leadership.

Darrin earned a doctoral degree in pharmacology from the University of Alberta and holds master’s and bachelor’s degrees in biology from the University of Waterloo.